Menu
Recruiting NCT05146336

CytOSorb TreatMent Of Critically Ill PatientS Registry

— Observational Septic Shock Acute Respiratory Distress Syndrome Trauma Rhabdomyolysis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: CytoSorb.
Who it may be relevant to
Registry conditions: Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Austria, Germany, Italy, Poland, Portugal +1
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting

Overview

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Interventions

  • Device CytoSorb
    Sorbent hemoperfusion system

Primary outcome measures

  • ICU mortality [Time frame: Through ICU discharge or date of death, whichever comes first [on average 7 days]]
  • In-hospital mortality [Time frame: Through hospital discharge or date of death, whichever comes first [on average 14 days]]

Eligibility criteria

Inclusion criteria

  • Planned OR actual CytoSorb® 300 mL device utilization
  • Informed consent for prospective registry participation

Exclusion criteria

  • Use of the CytoSorb® 300 mL device for antithrombotic removal only
  • Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only
  • The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Germany · 18 centers
  • Universitätsklinikum Aachen — Aachen
  • Herz- und Diabeteszentrum Nordrhein-Westfalen — Bad Oeynhausen
  • Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil Bochum — Bochum
  • Katholisches Klinikum Bochum, St. Josef-Hospital — Bochum
  • Universitätsklinikum Essen, Medizinische Intensivtherapie — Essen
  • Universitätsklinikum Essen, Nephrologie — Essen
  • Universitätsklinikum Essen, Thorax- und Kardiovaskuläre Chirurgie — Essen
  • Universitätsmedizin Göttingen, Allgemein-, Viszeral- und Kinderchirurgie — Göttingen
  • … and 10 more centers
Austria · 2 centers
  • Klinikum Klagenfurt am Wörthersee — Klagenfurt
  • Medizinische Universität Wien — Vienna
Italy · 2 centers
  • Ospedale Pediatrico Bambino Gesù — Roma
  • IRCCS Ospedale Casa Sollievo della Sofferenza — San Giovanni Rotondo
Poland · 2 centers
  • SP ZOZ Szpital Uniwersytecki w Krakowie — Krakow
  • Uniwersyteckim Spitalem Klinicznym im. Jana Mikulicza - Radeckiego we Wrocławiu — Wroclaw
Portugal · 2 centers
  • Unidade Local de Saúde de Coimbra E.P.E — Coimbra
  • ULS São José, Hospital Curry Cabral — Lisbon
Spain · 2 centers
  • Hospital Universitari Vall d'Hebron — Barcelona
  • Hospital Juan Ramón Jimenez — Huelva

Publications

  • Ferrer R, Thielmann M, Kribben A, Unglaube M, Tyczynski B, Kreutz J, Baumann A, Guenther U, Henzler D, Kirschning T, El-Essawi A, Gunther T, Bellgardt M, Bottari G, Aucella F, Hidalgo J, Teboul JL, Tomescu D, Klaus T, Fan W, Scheier J, Deliargyris EN, Taccone FS. The international, prospective CytOSorbⓇ treatMent Of critically ill patientS (COSMOS) registry: Interim results from the first 150 pati PMID 41180104
  • Taccone FS, Brunkhorst FM, Bottari G, Hidalgo J, Kribben A, Teboul JL, Tomescu D, Klaus T, Scheier J, Deliargyris E, Ferrer R. The COSMOS Registry of CytoSorb Hemoadsorption Therapy in Critically Ill Patients: Protocol for an International, Prospective Registry. JMIR Res Protoc. 2024 Nov 5;13:e55880. doi: 10.2196/55880. PMID 39500494

Identifiers

NCT: NCT05146336 · O06

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗